COST PER CLINICAL OUTCOMES WITH VEDOLIZUMAB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN BRAZIL

Tassia Decimoni  1     Gabriela Muricy  1     Haridarshan Patel  2     Dirk Demuth  3    
1 Takeda Pharmaceuticals International. Inc., São Paulo, Brazil
2 Immensity Consulting, Inc, Chicago, United States of America
3 Takeda Development Centre Europe Ltd, Global Outcomes Research, London, United Kingdom

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at office@ueg.eu

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing